{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-090232","form_type":"8-K","ticker":null,"cik":"0001722964","company_name":"Y-mAbs Therapeutics, Inc.","filed_at":"2025-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.780713+00:00","generated_at":"2026-05-17T06:30:34.417522+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Y-mAbs acquired by Perseus BidCo US; tender offer completed at $8.60/share, ~$413M total","bullets":["Approximately 39.8M shares (~87.22%) tendered; Purchaser accepted all validly tendered shares.","Merger closed Sep 16; each outstanding share (except excluded) converted to $8.60 cash.","Aggregate consideration ~$413M funded via cash on hand and short-term financing.","Shares to be delisted from Nasdaq; company will file Form 15 to suspend reporting obligations.","All prior directors and officers resigned; new board and officers appointed (Vanessa Wolfeler, Robert Duffield, Daniel Dolan)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-090232","json":"https://secwatch.observer/filing/0001104659-25-090232.json","markdown":"https://secwatch.observer/filing/0001104659-25-090232.md","text":"https://secwatch.observer/filing/0001104659-25-090232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722964/000110465925090232/0001104659-25-090232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722964/000110465925090232/tm2525998d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:30:34.417522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5141d9b025a6e9e46b2f9d510a055bdbac660579","claim":"Y-mAbs Therapeutics, Inc.: By-laws amended and restated in their entirety.","evidence_excerpt":"at the Effective Time, the Company’s by-laws (the “ By-Laws ”) were amended and restated in their entirety.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722964/000110465925090232/0001104659-25-090232-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"9dba2a1d7f71013e118e5aa997fcc81a2ae87e85","claim":"Y-mAbs Therapeutics, Inc.: Certificate of incorporation amended and restated in its entirety.","evidence_excerpt":"at the Effective Time, the certificate of incorporation of the Company (the “ Certificate of Incorporation ”) was amended and restated in its entirety.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722964/000110465925090232/0001104659-25-090232-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}